Press Releases May 13, 2026 09:00 AM

IBEX Limited Announces $20 Million Share Repurchase Program

IBEX Limited announces a $20 million share repurchase program reflecting confidence in growth and financial strength.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
IBEX

IBEX Limited, a leader in outsourced business services and AI-driven customer experience solutions, announced that its Board of Directors has authorized a $20 million share repurchase program to be executed over the next 12 months. The program aims to deploy capital efficiently while maintaining an aggressive investment strategy in business growth. The repurchases may be made via various market transactions and are subject to regulatory rules. The company plans to fund repurchases through existing cash and free cash flow, with flexibility to adjust or suspend the program if necessary.

IBEX Limited Announces $20 Million Share Repurchase Program
IBEX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • IBEX authorized a $20 million share repurchase program to enhance shareholder value.
  • Repurchases will be funded via existing cash balances and free cash flow, indicating strong financial health.
  • Company maintains focus on growth with ongoing aggressive investments in its AI-powered customer experience solutions.
  • Sectors impacted include technology, customer service outsourcing, AI, retail, e-commerce, healthcare, fintech, utilities, and logistics markets.

WASHINGTON, May 13, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, today announced that its Board of Directors has authorized a share repurchase program, under which the Company may repurchase up to $20 million of its common stock during the next 12 months (the “Share Repurchase Program”).

“Our new repurchase program reflects our confidence in the strength of our business, financial position, and growth trajectory,” said Bob Dechant, ibex CEO. “We remain focused on deploying capital thoughtfully and in a manner that drives value for our shareholders.”

The Company's proposed repurchases may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on the market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the Securities and Exchange Commission (the “SEC”) Rule 10b-18 and/or Rule 10b5-1 requirements.

The Board will review the Share Repurchase Program periodically and may authorize adjustment of its terms and size or suspend or discontinue the program. The Company expects to fund the repurchases under this program with its existing cash balance and free cash flow. The repurchase program will be executed consistent with the Company’s capital allocation strategy, which will continue to prioritize aggressive investments to grow the business.

The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion.

About ibex
ibex is a global leader in outsourced business services and AI-powered customer experience solutions, enabling the world’s best brands to deliver truly differentiated experiences for their customers. Leveraging a global team of more than 36,000 human CX experts – powered by the best AI technology, decades of CX innovation, and deep business insights – ibex engineers seamless, end-to-end customer journeys from AI agents to human agents at scale across retail, e-commerce, healthcare, fintech, utilities, technology, logistics, and more. Discover more at ibex.co and connect with us on LinkedIn. 

Investor Contact
Tom Colton and Greg Bradbury
Gateway Group, Inc.
949-574-3860
IBEX@gateway-grp.com

Media Contact
Dan Burris
ibex
Daniel.Burris@ibex.co


Risks

  • Share repurchase programs may reduce cash reserves, potentially limiting flexibility for future strategic investments or acquisitions.
  • Market volatility or failure to repurchase shares at advantageous prices may lessen the program's effectiveness.
  • Continued aggressive investment strategy may carry execution risks and could impact short-term financial performance.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026